With just days until sweeping new pharmaceutical tariffs take effect, one thing is clear: the companies least able to absorb the hit are the ones facing the most uncertainty. As BIO President and CEO John F. Crowley warns in @Biocentury, these tariffs would raise costs, impede domestic manufacturing, and divert scarce resources away from the research that drives American innovation. Read more: https://www.biocentury.com/article/660836/twelve-days-to-go-and-pharma-tariff-rules-are-a-total-mystery